Natera shares gain more than 4% after record Q2 revenue and raised full-year outlook

Traders Union
All News
Stocks
Natera surges 4.34% today on gains

Highlights

Natera stock reported a 40% year-over-year revenue increase to $753 million in the second quarter of 2025, exceeding analyst estimates.
Executive Chairman Matthew Rabinowitz sold approximately 101,000 to 102,000 shares for about $34.8 million under Rule 10b5-1 plans.
Shares of Natera are in a bullish trend near session highs at $360.32, with momentum indicators strong but short-term oscillators suggest potential overbought conditions and a forecasted trading range of $343.98 to $376.67 for the next five days.

Insider share sales and earnings beat as oncology test boosts sentiment

Natera reported that Executive Chairman Matthew Rabinowitz sold around 101,000–102,000 shares in open-market transactions on September 14 and 15, 2026, totaling approximately $34.8 million, under pre-established Rule 10b5-1 plans. The company also announced record revenue for the second quarter of 2025, rising 40% year-over-year to about $753 million, attributed to strong performance in its oncology segment, especially from the Signatera cancer-monitoring test. Revenue results surpassed analyst estimates, and the company raised its full-year guidance. Natera presented these achievements at the 2026 Global Healthcare Conference.

Anton Kharitonov, expert at Traders Union, notes that Natera’s price rally was fueled by record revenue, but the insider selling by the Executive Chairman raises a red flag. He observes that technical overbought signals, such as elevated RSI and CCI, increase the likelihood of near-term exhaustion. Kharitonov highlights that while bullish momentum persists across time frames, the ongoing selling by top management could undermine sentiment and trigger volatility. The elevated volatility and near-session-high trading also suggest susceptibility to rapid reversals if the mood shifts. "Despite headline growth, aggressive insider selling and pronounced overbought readings make me wary of further upside."

Viktoras Karapetjanc, expert at Traders Union, sees Natera’s robust 40% revenue growth and improved full-year guidance as strong fundamental drivers. He emphasizes the exceptional demand for the oncology segment and positive sentiment following analyst-beating results and the Global Healthcare Conference presentation. Karapetjanc believes the bullish structure remains intact above key support, with investor attention drawn to the Signatera test’s momentum. "With fundamentals and market appetite aligned, I expect further growth and see multiple setups developing on any consolidation."

Jainam Mehta, market strategist, points to the alignment above all the main moving averages as confirmation of medium-term strength in Natera. He notes that the 75% probability of upward movement is supported by momentum, but the overbought oscillators hint at a possible tactical pullback. Mehta suggests a breakout above $361.41 could attract momentum traders, while a fall below $343.98 may offer a contrarian entry. "If the stock consolidates, I’ll be watching for a directional push out of this channel for fresh trade opportunities."

Upward breaks and overbought signals as buyers drive momentum

Natera is trading above its 20-day, 50-day, and 200-day moving averages ($331.05, $300.69, $239.38, respectively), reflecting short-, medium-, and long-term bullish momentum. The nearest ceiling is the session high at $361.41 and the floor is the weekly high at $357.15; broader moving averages confirm a positive trend structure. Momentum readings are constructive, with both the MACD and Average Directional Index (ADX) signaling a buy. The Relative Strength Index (RSI) stands at 65.9 and leans bullish, but the Commodity Channel Index (CCI) at 197.78 and Bull/Bear Power (BBP) at 23.87 both flag the stock as overbought. Stochastic RSI warns of potential short-term exhaustion. BBP indicates buyers dominate intraday action and the Awesome Oscillator (AO) aligns with upward momentum. Today, the stock trades near the session high with intraday volatility at 3.78%. The tone remains strong heading into midday, but short-term oscillators highlight possible overheating.

In a recent review, AMC Entertainment's strong earnings underscored a rebound in theatrical markets amid broader industry challenges and corporate developments. Against this backdrop, Natera’s robust revenue growth and upwardly revised guidance add a positive sector dimension, with short-term volatility creating a tactical range defined by $343.98 to $376.67 for active traders to monitor.

Source of Data: NTRA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.